Home
About
Overview
Sharing Data
ORCID
Help
History (9)
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Risk of Procedural Hemorrhage.
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
Thromboembolic Disease in Patients with Metastatic Femoral Lesions: A Comparison Between Prophylactic Fixation and Fracture Fixation.
CXCL4's "Gliful" subversion of BM in MPN.
See All 9 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
CXCL4's "Gliful" subversion of BM in MPN.
CXCL4's "Gliful" subversion of BM in MPN. Blood. 2020 10 29; 136(18):1999-2000.
View in:
PubMed
subject areas
Bone Marrow
Hematopoietic Stem Cell Transplantation
Humans
Inflammation
Platelet Function Tests
Primary Myelofibrosis
authors with profiles
Sandeep Gurbuxani